Heart failure & cardiomyopathies
Efficacy and Safety of SGLT2 Inhibitors in Heart Failure: Observational Evidence in Geriatric Patients—AGING-HF
Authors' conclusion
In this elderly population with high comorbidity, SGLT2i therapy was associated with substantial reductions in mortality and HF rehospitalization, and showed good tolerability and an acceptable safety profile.
Study context
- Population
- Elderly patients hospitalised for acute heart failure (HF) in geriatric units (mean age 90 years, mean Charlson Comorbidity Index 8.2)
- Participants
- 496 patients
- Exposure
- SGLT2i plus standard HF treatment vs standard HF treatment alone
- SGLT2in = 260
- Controln = 236reference
- Outcome
- All-cause mortality, HF rehospitalisations and adverse events
- Follow-up
- 1 year
Methodological detailsmulticentre, 3 geriatric units, multivariable adjustment
- Multicentre
- 3 geriatric units
- Multivariable adjustment
Main finding
As reported in the abstract
SGLT2i vs ControlHazard ratio (95% CI)P value
All-cause mortality
0.67(0.46–0.98)
P = 0.031HF rehospitalization
0.64(0.42–0.97)
P = 0.037Composite outcome
0.60(0.44–0.82)
P = 0.001Observational data: associations, not effects.
Further findings
- No significant interaction between LVEF status and SGLT2i use
- P for interaction = 0.12
Safety
- Urinary and genital infections; treatment discontinuation — SGLT2i
- 2.7%
- Urinary and genital infections; treatment discontinuation: 2.7% = treatment discontinuation
Urinary and genital infections; treatment discontinuation
- Urinary and genital infections more frequently reported with SGLT2i
Original publication
Efficacy and Safety of SGLT2 Inhibitors in Heart Failure: Observational Evidence in Geriatric Patients—AGING-HF. Circ Heart Fail. Published 20 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →